Opdualag Den europeiske union - norsk - EMA (European Medicines Agency)

opdualag

bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanom - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.

Mezavant 1200 mg Norge - norsk - Statens legemiddelverk

mezavant 1200 mg

takeda pharmaceuticals international ag ireland branch - mesalazin - enterodepottablett - 1200 mg

Naloxon Hameln 0.4 mg/ ml Norge - norsk - Statens legemiddelverk

naloxon hameln 0.4 mg/ ml

hameln pharma gmbh - naloksonhydrokloriddihydrat - injeksjons-/infusjonsvæske, oppløsning - 0.4 mg/ ml

Carmustine Macure 100 mg Norge - norsk - Statens legemiddelverk

carmustine macure 100 mg

macure pharma aps - karmustin - pulver og væske til konsentrat til infusjonsvæske, oppløsning - 100 mg

Cidofovir Macure 75 mg/ ml Norge - norsk - Statens legemiddelverk

cidofovir macure 75 mg/ ml

macure pharma aps - sidofovirdihydrat - konsentrat til infusjonsvæske, oppløsning - 75 mg/ ml

Foskarnetnatriumheksahydrat Tillomed 24 mg/ ml Norge - norsk - Statens legemiddelverk

foskarnetnatriumheksahydrat tillomed 24 mg/ ml

tillomed pharma gmbh - schönefeld - foskarnetnatriumheksahydrat - infusjonsvæske, oppløsning - 24 mg/ ml

Fenylefrin Unimedic 0.05 mg/ ml Norge - norsk - Statens legemiddelverk

fenylefrin unimedic 0.05 mg/ ml

unimedic pharma ab - fenylefrinhydroklorid - injeksjonsvæske, oppløsning - 0.05 mg/ ml

Fenylefrin Unimedic 0.1 mg/ ml Norge - norsk - Statens legemiddelverk

fenylefrin unimedic 0.1 mg/ ml

unimedic pharma ab - fenylefrinhydroklorid - injeksjonsvæske, oppløsning - 0.1 mg/ ml

Teriparatide Sun Den europeiske union - norsk - EMA (European Medicines Agency)

teriparatide sun

sun pharmaceutical industries europe b.v. - teriparatide - osteoporosis; osteoporosis, postmenopausal - kalsiumhomeostase - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Resolor Den europeiske union - norsk - EMA (European Medicines Agency)

resolor

takeda pharmaceuticals international ag ireland - prucalopride succinate - forstoppelse - andre stoffer for forstoppelse - resolor er indisert for symptomatisk behandling av kronisk forstoppelse hos voksne som laksemidler ikke gir tilstrekkelig lindring.